Daclizumab therapy for multiple sclerosis

scientific article

Daclizumab therapy for multiple sclerosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1011949884
P356DOI10.1007/S13311-012-0147-4
P8608Fatcat IDrelease_pkmodsdxsffhnmbr5lw5v5p3dq
P3181OpenCitations bibliographic resource ID3887981
P932PMC publication ID3557356
P698PubMed publication ID23055048

P2093author name stringBibiana Bielekova
P2860cites workDaclizumab for relapsing remitting multiple sclerosisQ24200496
Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptorQ24312136
Development and function of T cells in mice rendered interleukin-2 deficient by gene targetingQ24318910
Structural basis for NKG2A/CD94 recognition of HLA-E.Q24336854
A humanized antibody that binds to the interleukin 2 receptorQ24600912
Natural killer cells and autoimmunityQ24793284
IL-15Ralpha recycles and presents IL-15 In trans to neighboring cellsQ28214975
Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptorsQ28282381
Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartmentQ28587823
Risk alleles for multiple sclerosis identified by a genomewide studyQ29614890
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationQ33194554
NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritisQ33381309
IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor productionQ33396971
Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2.Q33854381
Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell deathQ33876302
Inducible IL-2 production by dendritic cells revealed by global gene expression analysis.Q34088526
The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling.Q34152180
NK cells and NKT cells in innate defense against viral infectionsQ34332682
The biology of human natural killer-cell subsetsQ34430869
Control of T-cell activation by CD4+ CD25+ suppressor T cellsQ34448423
Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cellsQ34501407
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon betaQ34514715
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.Q34596171
CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytesQ34596186
Monoclonal antibodies in MS: mechanisms of actionQ34615261
The IL-2/IL-15 receptor systems: targets for immunotherapyQ34630134
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical resultsQ34665233
An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cellsQ34893862
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapyQ34949098
Human NK cells and their receptors.Q35035740
Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosisQ35091437
The main function of IL-2 is to promote the development of T regulatory cellsQ35213797
Intrathecal effects of daclizumab treatment of multiple sclerosisQ35635127
Unraveling human natural killer cell deficiencyQ35780328
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptorsQ36351101
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trialQ36397083
Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralizationQ36402763
Lymphoid neogenesis in chronic inflammatory diseases.Q36405080
Search for organising principles: understanding in systems biologyQ36628523
Maternal acceptance of the fetus: true human toleranceQ36752550
Human natural killer cellsQ36787596
IL-2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells.Q36992146
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.Q37159538
CD25 as an immune regulatory molecule expressed on myeloid dendritic cellsQ37300261
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cellsQ37313533
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.Q37343849
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosisQ37354974
Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.Q37418499
Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responsesQ37712459
Lymphoid tissue inducer cells: innate cells critical for CD4+ T cell memory responses?Q37977138
Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-TacQ39168921
Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factorsQ39577528
IL-2 receptors in adult T-cell leukemia: a target for immunotherapyQ39601718
Functional and morphologic characterization of human T cells continuously grown in vitroQ39818384
Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune responseQ41472662
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cellsQ41475516
Interleukin-2, interleukin-15, and their receptorsQ41722182
Cutting edge: lymphoid tissue inducer cells maintain memory CD4 T cells within secondary lymphoid tissueQ42325266
Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosisQ43539775
The monocyte interleukin-2 receptor light chain: production of cell-associated and soluble interleukin-2 receptor by monocytesQ44493843
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaQ44597307
Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2.Q45840886
IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosisQ46106529
Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A.Q46211971
Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral bloodQ46655432
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trialsQ47242957
Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation.Q47871733
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.Q48200750
Journal club: Intrathecal effects of daclizumab treatment of multiple sclerosisQ48491256
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosisQ48949792
A role for natural killer cells in the immunopathogenesis of multiple sclerosis.Q50876710
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.Q51027456
Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes.Q55044269
CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunityQ57265370
Lineage Relationship Analysis of RORγt+Innate Lymphoid CellsQ57520258
Immune responses in interleukin-2-deficient miceQ58194363
Accumulation of CD16−CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy deciduaQ67700611
The interleukin-2 receptor in human monocytes and macrophages: regulation of expression and release of the alpha and beta chains (p55 and p75)Q68097686
Cytokine production by CD16–CD56bright natural killer cells in the human early pregnancy deciduaQ72085502
Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor betaQ72287439
Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factorQ72609371
Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction eventsQ73370304
Human IL-2 receptor alpha chain deficiencyQ73952904
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cellsQ74602353
Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in childrenQ74617252
The use of antibodies against the IL-2 receptor in transplantationQ77485579
Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study GroupQ78106881
Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbersQ78404451
Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartmentQ78409843
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibodyQ80896193
CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activationQ80967934
The structure of interleukin-2 complexed with its alpha receptorQ81810296
Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantationQ84488242
Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosisQ84565920
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectmultiple sclerosisQ8277
P304page(s)55-67
P577publication date2013-01-01
P1433published inNeurotherapeuticsQ15716631
P1476titleDaclizumab therapy for multiple sclerosis
P478volume10

Reverse relations

cites work (P2860)
Q38397484A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.
Q37502636Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis
Q50871333Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Q36691970Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
Q37136498Cytokine Therapies in Neurological Disease
Q47959279Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Q38604207Daclizumab for the treatment of multiple sclerosis
Q39175716Daclizumab for the treatment of relapsing-remitting multiple sclerosis
Q33589947Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis
Q35619174Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
Q43905322Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis
Q37657070Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis
Q39140303Daclizumab: A Review in Relapsing Multiple Sclerosis
Q39434495Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis
Q64106331Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis
Q37558843Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
Q38315992Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
Q52619984Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
Q55401140Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis.
Q38837294Further understanding of the immunopathology of multiple sclerosis: impact on future treatments
Q55286986Immunosuppressant Peptide Abu-TGIRIS-Abu-NH2 and its Application for Treatment of Multiple Sclerosis.
Q34356481In search of magic bullets: the golden age of immunotherapeutics.
Q30908652Infection risk in patients on multiple sclerosis therapeutics
Q38144976Infectious complications of immune modulatory agents.
Q38570574Innate and adaptive immune responses in the CNS.
Q38111620Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.
Q38364547Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.
Q38153471Multiple sclerosis treatment and infectious issues: update 2013.
Q41459008New candidates for CD4 T cell pathogenicity in experimental neuroinflammation and multiple sclerosis.
Q39021942Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.
Q36521247Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
Q40962441Pharmacodynamic effects of daclizumab in the intrathecal compartment
Q36585726Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
Q37459065Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
Q37286272Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens
Q93048503Relationship between Multiple Sclerosis-Associated IL2RA Risk Allele Variants and Circulating T Cell Phenotypes in Healthy Genotype-Selected Controls
Q27693249Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis
Q36975701Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
Q38114422Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis
Q35012335Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma
Q90531326Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
Q38291845The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.
Q90706071The Potential for Cancer Immunotherapy in Targeting Surgery-Induced Natural Killer Cell Dysfunction
Q30252875The effects of interleukin-2 on immune response regulation
Q30730505The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis
Q38089599The role of natural killer cells in multiple sclerosis and their therapeutic implications
Q45066717The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
Q37030744Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.

Search more.